Enhanced pharmacist care for mental health in Alberta
Mental Health Assessment and Prescribing by Alberta Pharmacists (MAP-AP)
This study is testing whether extra support from pharmacists can help people in Alberta who are newly diagnosed with depression or anxiety feel better compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 94 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Alberta Academic / other |
| Locations | 1 site (Edmonton, Alberta) |
| Trial ID | NCT04410575 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the impact of enhanced pharmacist care, facilitated by additional prescribing authorization, for patients newly diagnosed with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD) in Alberta. The study compares this enhanced care to standard pharmacist and physician care, focusing on interventions such as clinical monitoring, patient education, and medication management. Primary objectives include assessing clinical response rates and patient satisfaction, while secondary objectives explore the sustainability of pharmacist interventions. The trial aims to improve patient outcomes through optimized medication management and support.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been newly diagnosed with MDD and/or GAD and are starting pharmacotherapy.
Not a fit: Patients who may not benefit include those with severe mental health conditions, significant comorbidities, or those residing outside Alberta.
Why it matters
Potential benefit: If successful, this approach could lead to improved management of MDD and GAD, enhancing patient outcomes and satisfaction.
How similar studies have performed: Other studies have shown promising results with pharmacist-led interventions in mental health care, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Adults (≥ 18 years of age) newly diagnosed with MDD and/or GAD, including: * Patients starting on medications for the management of adults with MDD * Patients starting on medications for the management of GAD Exclusion Criteria: * Pregnancy * Non-Alberta residents * Unwilling or unable to participate in regular follow-up visits * Unwilling to participate/sign consent form * ≥2 suicide attempts per year * Severe, psychotic, and catatonic depression * History of and/or current substance abuse, intoxication, addiction or withdrawal * Patients diagnosed with comorbid anxiety disorders other than GAD, including: panic -disorder, agoraphobia, specific phobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder * Patients diagnosed with comorbid depressive disorder other than MDD, including: depressive disorder due to another medical condition (e.g. hypothyroidism, MS, OSA, -Parkinsons, stroke, TBI, Vitamin B12 insufficiency, Huntington disease, adrenal insufficiency, mononucleosis, systemic lupus erythematosus), adjustment disorder with depressed mood * Patients diagnosed with concurrent ADHD, bipolar disorder, schizophrenia and schizoaffective disorder
Where this trial is running
Edmonton, Alberta
- University of Alberta — Edmonton, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Yazid Al Hamarneh, BSc (Pharm), PhD, CDM — University of Alberta
- Study coordinator: Yazid Al Hamarneh, BSc (Pharm), PhD, CDM
- Email: yazid.alhamarneh@ualberta.ca
- Phone: (780) 492-9608
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.